We are pleased to announce our collaboration with the Croatian Health Insurance Fund (Hrvatski Zavod Za Zdravstvene Osiguranje), which now enables its patients to access Pluvicto® (PSMA radioligand therapy) within the approved indication in an outpatient setting!

This is a great step for patient care—but just a small step for the patient, as outpatient therapy eliminates the need for hospitalization, with each session lasting only about one hour.

With the recent FDA approval of Pluvicto for use before chemotherapy, we hope that EMA and other public health insurers in Europe will soon follow.

💡 Outpatient, patient-friendly, effective!